Prospective study of rabbit antithymocyte globulin and cyclosporine for aplastic anemia from the EBMT Severe Aplastic Anaemia Working Party

Blood

Volumn 119, Issue 23, 2012, Pages 5391-5396

  Marsh, Judith C ^a   Bacigalupo, Andrea ^b   Schrezenmeier, Hubert ^c   Tichelli, Andre ^d   Risitano, Antonio M ^e   Passweg, Jakob R ^d   Killick, Sally B ^f   Warren, Alan J ^g   Foukaneli, Theodora ^g   Aljurf, Mahmoud ^h   Al Zahrani, H A ^h   Schafhausen, Philip ⁱ   Roth, Alexander ^j   Franzke, Anke ^k   Brummendorf, Tim H ^l   Dufour, Carlo ^m   Oneto, Rosi ^b   Sedgwick, Philip ⁿ   Barrois, Alain ^o   Kordasti, Shahram ^a   Elebute, Modupe O ^a   Mufti, Ghulam J ^a   Socie, Gerard ^p   more..

^a KING'S COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF GENOA   (Italy)

^c UNIVERSITY OF ULM   (Germany)

^d UNIVERSITY HOSPITAL BASEL   (Switzerland)

^e UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^f ROYAL BOURNEMOUTH HOSPITAL   (United Kingdom)

^g UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^h KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

ⁱ UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^j UNIVERSITY HOSPITAL ESSEN   (Germany)

^k HANNOVER MEDICAL SCHOOL   (Germany)

^l UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^m G GASLINI INSTITUTE   (Italy)

ⁿ ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^o LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^p SAINT LOUIS HOSPITAL   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; GENZYME; HORSE LYMPHOCYTE ANTIBODY; LYMPHOCYTE ANTIBODY; RABBIT ANTITHYMOCYTE GLOBULIN; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; APLASTIC ANEMIA; ARTHRALGIA; ARTICLE; AVASCULAR NECROSIS; BLEEDING; BRAIN HEMORRHAGE; CAUSE OF DEATH; CD4+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DIABETES MELLITUS; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HUMAN CELL; HYPERTENSION; HYPERTRANSAMINASEMIA; HYPOTHYROIDISM; IN VITRO STUDY; INFECTION; KIDNEY DISEASE; KIDNEY FAILURE; MALE; MORTALITY; MULTICENTER STUDY; MULTIPLE ORGAN FAILURE; MYCOSIS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PILOT STUDY; PNEUMONIA; POST TREATMENT SURVIVAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RASH; SEPSIS; TH1 CELL; TH17 CELL; TH2 CELL; TREATMENT RESPONSE;

EID: 84862548491     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-02-407684     Document Type: Article

References (37)

1. European Blood and Marrow Transplant Group Severe Aplastic Anaemia Working Party. The complete treatment algorithm for SAA (prepared by EBMT SAAWP). http://www.ebmt.org/5WorkingParties/AAWP/wparties-aa3.html. Accessed January 2011.
2. Marsh JC, Ball SE, Cavenagh J, et al. Guidelines for the diagnosis and management of aplastic anaemia. Br J Haematol. 2009;147(1):43-70.
3. Rosenfeld S, Follmann D, Nunez O, Young NS. Antithymocyte globulin and Ciclosporin for severe aplastic anemia: association between hematologic response and long-term outcome [see comment]. JAMA. 2003;289(9):1130-1135. (Pubitemid 37430327)
4. Frickhofen N, Heimpel H, Kaltwasser JP, et al. Antithymocyte globulin with or without cyclosporin A: 11-year follow-up of a randomized trial comparing treatments of aplastic anemia. Blood. 2003;101(4):1236-1242. (Pubitemid 36182490)
5. Locasciulli A, Oneto R, Bacigalupo A, et al. Outcome of patients with acquired aplastic anemia given first-line bone marrow transplantation or immunosuppressive treatment in the last decade: a report from the European Group for Blood and Marrow Transplantation (EBMT). Haematologica. 2007;92(1):11-18. (Pubitemid 46232653)
6. Tichelli A, Schrezenmeier H, Socie G, et al. A randomized controlled study in newly-diagnosed severe aplastic anemia patients receiving antithymocyte globulin, ciclosporin, with or without G-CSF. Blood. 2011;117(17):4434-4441.
7. Gluckman E, Rokicka-Milewska R, Hann I, et al. Results and follow-up of a phase III randomized study of recombinant human-granulocyte stimulating factor as support for immunosuppressive therapy in patients with severe aplastic anaemia. Br J Haematol. 2002;119(4):1075-1082. (Pubitemid 35463836)
8. Teramura M, Kimura A, Iwase S, et al. Treatment of severe aplastic anemia with antithymocyte globulin and cyclosporin A with or without G-CSF in adults: a multicenter randomized study in Japan. Blood. 2007;110(6):1756-1761. (Pubitemid 47443885)
9. Marsh J, Schrezenmeier H, Marin P, et al. A prospective randomized multicenter study comparing cyclosporin alone versus the combination of antithymocyte globulin and cyclosporin for treatment of patients with nonsevere aplastic anemia: a report from the European blood and marrow transplant (EBMT) severe aplastic anaemia working party. Blood. 1999;93(7):2191-2195. (Pubitemid 29153619)
10. Di Bona E, Rodeghiero F, Bruno B, et al. Rabbit antithymocyte globulin (r-ATG) plus cyclosporine and granulocyte colony stimulating factor is an effective treatment for aplastic anaemia patients unresponsive to a first course of intensive immunosuppressive therapy: Gruppo Italiano Trapianto di Midollo Osseo (GITMO). Br J Haematol. 1999;107(2):330-334. (Pubitemid 29530219)
11. Scheinberg P, Nunez O, Young N. Retreatment with rabbit antithymocyte globulin and Ciclosporin for patients with relapsed or refractory severe aplastic anaemia. Br J Haematol. 2006;133(6):622-627. (Pubitemid 43742776)
12. Kosaka Y, Yagasaki H, Sano K, et al. Prospective multicenter trial comparing repeated immunosuppressive therapy with stem-cell transplantation from an alternative donor as second-line treatment for children with severe and very severe aplastic anemia. Blood. 2008;111(3):1054-1059. (Pubitemid 351222518)
13. Tichelli A, Passweg J, Nissen C, et al. Repeated treatment with horse antilymphocyte globulin for severe aplastic anaemia. Br J Haematol. 1998;100(2):393-400. (Pubitemid 28131078)
14. Scheinberg P, Fischer SH, Li L, et al. Distinct EBV and CMV reactivation patterns following anti-body-based immunosuppressive regimens in patients with severe aplastic anemia. Blood. 2007;109(8):3219-3224. (Pubitemid 46578057)
15. Brennan DC, Flavin K, Lowell JA, et al. A randomized, double-blinded comparison of thymoglobulin versus Atgam for induction immunosuppressive therapy in adult renal transplant recipients. Transplantation. 1999;67(7):1011-1018. (Pubitemid 29200852)
16. Feng X, Kajigaya S, Solomou E, et al. Rabbit ATG but not horse ATG promotes expansion of functional CD4+ CD25highFOXP3+ regulatory T cells in vitro. Blood. 2008;111(7):3675-3683.
17. Scheinberg P, Nunez O, Weinstein B, et al. Horse versus rabbit antithymocyte globulin in acquired aplastic anemia. N Engl J Med. 2011;365(5):430-438.
18. Atta EA, D Dias SP, Marra VLN, de Azevedo AM. Comparison between horse and rabbit antithymocyte globulin as first-line treatment for patients with severe aplastic anemia: a single centre retrospective study. Ann Hematol. 2010;89(9):851-59.
19. Halkes CJM, Brand A, von dem Borne PA, et al. Increasing the dose of rabbit-ATG does not lead to a higher response rate in the first-line treatment of severe aplastic anaemia. Bone Marrow Transplant. 2011;46:S90-S389;p1176, p5373.
20. Kadia T, Ravandi F, Garcia-Manero G, et al. Updated results of combination cytokine immunotherpay in the treatment of aplastic anaemia and myelodysplastic syndromes (MDS) [abstract]. Blood (ASH Annual Meeting Abstracts). 2010;116(Suppl):2920.
21. Saracco P, Lorenzati A, Oneto R, et al. Italian Registry of Pediatric Acquired Aplastic Anaemia: a retrospective study. Bone Marrow Transplant. 2011;46:S90-S389.
22. Vallejo C, Montesinos P, Rosell A, et al. Comparison between lymphoglobuline- and thymoglobuline-based immunosuppressive therapy as first-line treatment for patients with aplastic anemia [abstract]. Blood (ASH Annual Meeting Abstracts). 2009;114(22):3194a.
23. Afable MG, Shaik M, Sugimoto Y, et al. Efficacy of rabbit antithymocyte globulin in severe aplastic anemia. Haematologica. 2011;96(9):1269-1275.
24. Yamazaki H, Saito C, Sugimori N, et al. Thymoglobuline is as effective as Lymphoglobuline in Japanese patients with aplastic anemia possessing increased glycosylphosphatidylinositol-anchored protein (GPI-AP) deficient cells [abstract]. Blood (ASH Annual Meeting Abstracts). 2011;118(21):1339.
25. Jeong D-C, Chung NG, Lee JW, Jang P, Cho B, Kim H-K, Long-term outcome of immunosuppressive therapy with rabbit Antithymocyte Globulin (rATG) for childhood severe aplastic anemia for 15 years [abstract]. Blood. 2011;118(21):1346.
26. Brodsky RA, Chen AR, Dorr D, et al. High dose cyclophosphamide for severe aplastic anemia: long-term follow-up. Blood. 2010;115(11):2136-2141.
27. Solomou EE, Rezvani K, Mielke S, et al. Deficient CD4+ CD25+ FOXP3+ T regulatory cells in acquired aplastic anemia. Blood. 2007;110(5):1603-1606. (Pubitemid 47443977)
28. de Latour RP, Visconte V, Takaku T, et al. Th17 immune responses contribute to the pathophysiology of aplastic anemia. Blood. 2010;116(20):4175-4184.
29. Kordasti S, Marsh J, Al-Khan S, et al. Functional characterizations of CD4+ T cells in aplastic anemia. Blood. 2012;119(9):2033-2043.
30. Kennedy-Nasser A, Leukng K, Mahiajan A, et al. Comparable outcomes of matched-related and alternative donor stem cell transplantation for pediatric severe aplastic anemia. Biol Blood Marrow Transplant. 2006;12(12):1277-1284. (Pubitemid 44858261)
31. European Blood and Marrow Transplant Group. Severe aplastic anaemia Working Party. Rabbit ATG for Aplastic Anaemia treatment: a backward step? Lancet. 2011;378(9806):1831-1833.
32. Bacigalupo A, Socie G, Lanino E, et al. Severe Aplastic Anemia Working Party of the European Group for Blood and Marrow Transplantation. Fludarabine, cyclophosphamide, antithymocyte globulin, with or without low dose total body irradiation, for alternative donor transplants, in acquired severe aplastic anemia: a retrospective study from the EBMT-SAA working party. Haematologica. 2010;95(6):976-982.
33. Marsh JC, Gupta V, Lim Z, et al. Alemtuzumab with fludarabine and cyclophosphamide reduces chronic graft versus host disease after allogeneic stem cell transplantation for acquired aplastic anemia. Blood. 2011;118(8):2351- 2357.
34. Risitano AM, Selleri C, Serio B, et al. Alemtuzumab is safe and effective as immunosuppressive treatment for aplastic anaemia and single-lineage marrow failure: a pilot study and a survey from the EBMT WPSAA. Br J Haematol. 2009;148(5):791-796.
35. Kim H, Min YJ, Baek JH, et al. A pilot dose-escalation study of alemtuzumab plus cyclosporine for patients with bone marrow failure syndrome. Leuk Res. 2009;33(2):222-231.
36. Gómez-Almaguer D, Jaime-Perez JC, Garza-Rodriguez V, et al. Subcutaneous alemtuzumab plus cyclosporine for the treatment of aplastic anemia. Ann Hematol. 2010;89(3):299-303.
37. Scheinberg P, Nunez O, Weinstein B, Scheinberg P, Wu CO, Young NS. Activity of alemtuzumab monotherapy in treatment-naive, relapsed, and refractory severe acquired aplastic anemia. Blood. 2012;119(2):345-354.